New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M Malaria Vaccine in African Children

• Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year• To date 25 million doses manufactured and ready for roll-out by

Related Keywords

India ,Mali ,Kenya ,Tanzania ,Burkina Faso ,Johnc Jacobs ,Adar Poonawalla ,Alassane Dicko ,Adrian Hill ,Oxford University ,World Health Organization ,University Of Oxford ,Serum Institute Of India Pvt Ltd ,Serum Institute Of India ,Serum Institute ,India Pvt Ltd ,Principal Investigator ,Matrixm Phase ,